Vioxx

A Free Service Provided By www.FactsOfLaw.com
Home

Sponsored Links

 


Click Above

Legal Topics

Arbitration and Mediation
Bankruptcy
Bextra
Car Accidents
Celebrex
Child Support
Child Custody & Visitation

Copyright Law
Criminal Law
Dangerous Drugs
Death
Divorce
DUI Drunk Driving

Elderly Laws
Employees' Rights
Estate Planning
Family Law
Fen-Phen
Immigration Law

Lawsuits
Lemon Law
Marriage
Medical Malpractice
Megan's Law
Meridia
Mesothelioma & Asbestos

Mold
Probate & Estates
Product Recalls
Real Estate

Statute of Limitations

Taxes & the IRS
Traffic Violations
Vioxx
Wills
Workers' Compensation
Work Related Injury

Legal Kits

Privacy Policy

 

Facts - Books - News    U.S. Facts Of Law:

Vioxx, Market Withdrawal

VIGOR study

The VIGOR study, published in 2000, had indicated a significant 4-fold increased risk of acute myocardial infarction (heart attack) in rofecoxib patients when compared with naproxen patients (0.4% vs 0.1%, RR 0.25) over the 12 month span of the study. There was no significant difference in the mortality from cardiovascular events between the two groups. Nor was there any significant difference in the rate of myocardial infarction between the rofecoxib and naproxen treatment groups in patients without high cardiovascular risk. The difference in overall risk was accounted for by the patients meeting the criteria for low-dose aspirin prophyalxis of secondary cardiovascular events (previous myocardial infarction, angina, cerebrovascular accident, transient ischemic attack, angioplasty, or coronary bypass), but who were excluded from taking low-dose aspirin in the initial design study. Once this risk was noted, Merck notified investigators in other rofecoxib studies to modify allow high-risk patients to take low-dose aspirin. (Bombardier et al., 2000)

Merck's scientists interpreted the finding as a protective effect of naproxen in reducing the risk of MI in high cardiovascular risk patients by 80 percent (which some commentators have noted would make naproxen three times as effective as aspirin). The results of the VIGOR study were submitted to the United States Food and Drug Administration (FDA) in February 2001, which led to the introduction, in April 2002, of warnings on Vioxx labeling concerning the increased risk of cardiovascular events (heart attack and stroke).

In sum, the VIGOR study suggested that medium-term use of rofecoxib resulted in nearly four-times the risk of suffering a heart attack or stroke in patients already at high risk of adverse cardiovascular events compared to patients receiving a placebo. There was no difference in risk for patients with normal cardiovascular risk.

APPROVE study

In 2001, Merck commenced the APPROVe (Adenomatous Polyp Prevention on Vioxx) study, a three year trial with the primary aim of evaluating the efficacy of rofecoxib for the prophylaxis of colorectal polyps. Celecoxib had already been approved for this indication, and it was hoped to add this to the indications for rofecoxib as well. An additional aim of the study was to further evaluate the cardiovascular safety of rofecoxib.

The APPROVe study was terminated early when the preliminary data from the study showed an increased relative risk of adverse thrombotic cardiovascular events (including heart attack and stroke), beginning after 18 months of rofecoxib therapy. In patients taking rofecoxib, versus placebo, the relative risk of these events was 1.92 (rofecoxib 1.50 events vs placebo 0.78 events per 100 patient years). The results from the first 18 months of the APPROVe study did not show an increased relative risk of adverse cardiovascular events. (Bresalier et al., 2005) Previous Phase III clinical trials had also not shown this trend. (Swan, 2004)

In sum, the APPROVe study suggested that long-term use of of rofecoxib resulted in nearly twice the risk of suffering a heart attack or stroke compared to patients receiving a placebo.

Withdrawal

Merck publicly announced the Vioxx market withdrawal of the drug from the market worldwide on September 30, 2004.

In addition to its own studies, on September 23, 2004 Merck apparently received information about new research by the FDA that supported previous findings of increased risk of heart attack among rofecoxib users (Grassley, 2004). FDA analysts estimated that Vioxx caused between 88,000 and 139,000 heart attacks, 30 to 40 percent of which were probably fatal, in the five years the drug was on the market.

On November 5 the medical journal The Lancet published a meta-analysis of the available studies on the safety of rofecoxib (Jüni et al., 2004). The authors concluded that, owing to the known cardiovascular risk, rofecoxib should have been withdrawn several years earlier. The Lancet published an editorial which condemned both Merck and the FDA for the continued availability of rofecoxib from 2000 until the recall. Merck responded by issuing a rebuttal of the Jüni et al. meta-analysis (Merck & Co., 2004).

Other COX-2 inhibitors

It is currently unknown whether the increased risk of adverse cardiovascular events is common to all COX-2 inhibitors. Recent studies have demonstrated the increased risk of cardiovascular events associated with the use of celecoxib, valdecoxib and parecoxib. (Solomon et al., 2005; Nussmeier et al., 2005)

Newer and more specific COX-2 inhibitors, including etoricoxib (Arcoxia) and lumiracoxib (Prexige), are currently undergoing Phase III/IV clinical trials. It is likely that these trials will be extended in order to supply additional evidence of cardiovascular safety.

 

Vioxx Market Withdrawal Best Sellers from Amazon.com

Natural Alternatives To Vioxx, Celebrex & Other Anti-inflammatory Prescriptio...
by Carol Simontacchi
Amazon Price: $5.95

Poison Pills: The Untold Story of the Vioxx Drug Scandal
by Tom Nesi
Amazon Price: $17.13

Two COX-2 inhibitors left after Vioxx withdrawal: CV events not linked to oth...
by Elizabeth Mechcatie, Peggy Peck
Amazon Price: $5.95

Pressure building for FDA to mandate post-approval studies after Vioxx incide...
by Joe Pickett
Amazon Price: $5.95

More data fail to resolve issue of COX-2 class effect: little information on ...
by Alicia Ault
Amazon Price: $5.95


Newsfeed display by CaRP

Vioxx Market Withdrawal News

IMPORTANT NOTICE: The information provided by FactsOfLaw.com does not constitute legal advice or any other type of advice and is provided for educational purposes only without warranty of any kind. FactsOfLaw.com has not reviewed the information on this page for accuracy and is not responsible for any errors, omissions or inaccuracies.  For legal advice you should consult a licensed attorney. Source: wikipedia.org

 

Copyright © 2008 All Rights Reserved - FactsOfLaw.com